Patients with tuberculosis and the AG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.